ScholarIQanswers from OpenAlex & ORCID
Robert I. Haddad
ResearcherPublications, citations & collaboration network
Robert I. Haddad is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert I. Haddad have?
ScholarIQindexed works
Robert I. Haddad has 790 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert I. Haddad have?
ScholarIQcitation count
Robert I. Haddad has 40,317 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert I. Haddad?
ScholarIQh-index
Robert I. Haddad has an h-index of 92 in OpenAlex.
What is the i10-index of Robert I. Haddad?
ScholarIQi10-index
Robert I. Haddad has an i10-index of 294 in OpenAlex.
What is the ORCID of Robert I. Haddad?
ScholarIQorcid
The ORCID for Robert I. Haddad is on the source record.
What is the OpenAlex record for Robert I. Haddad?
ScholarIQopenalex
The OpenAlex for Robert I. Haddad is on the source record.
What are the most-cited papers on Robert I. Haddad?
ScholarIQmost cited works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao, Claire A. Margolis, Natalie I. Vokes, David Liu, Amaro Taylor‐Weiner, Stephanie A. Wankowicz, Dennis O. Adeegbe, Daniel Keliher, Bastian Schilling, Adam Tracy, Michael P. Manos, Nicole G. Chau, Glenn J. Hanna, Paz Polak, Scott J. Rodig, Sabina Signoretti, Lynette M. Sholl, Jeffrey A. Engelman, Gad Getz, Pasi A. Jänne, Robert I. Haddad, Toni K. Choueiri, David A. Barbie, Rizwan Haq, Mark M. Awad, Dirk Schadendorf, F. Stephen Hodi, Joaquim Bellmunt, Kwok‐Kin Wong, Peter S. Hammerman, Eliezer M. Van Allen
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad